selected scholarly activity
-
chapters
- What Islamic Bioethics Offers to Global Bioethics. 33-55. 2017
- NON-SMALL-CELL LUNG CANCER: BLEOMYCIN PLUS ETOPOSIDE AND CISPLATIN. 215-224. 1985
-
conferences
- Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed plus cisplatin versus cisplatin trial. Lung Cancer. S221-S221. 2005
- Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer. S231-S231. 2005
- Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model. Lung Cancer. S230-S230. 2005
- Use of forced vital capacity (FVC) measurement for the clinical management of malignant pleural mesothelioma (MPM): Observations from the pemetrexed plus cisplatin versus cisplatin study. Lung Cancer. S227-S227. 2005
- Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 1045-1045. 1997
- Validity of the QLQ-M28 and QLQ-V28 nausea and vomiting forms of the EORTC QLQ-C30. Quality of Life Research. 7-7. 1997
- Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP). European Journal of Cancer. 1204-1204. 1995
- POTENTIAL MANIPULATIONS TO RESTORE ABERRANT MYELOPOIESIS - THE ROLE OF NEW COLONY-STIMULATING FACTORS AND OTHER AGENTS. Canadian Journal of Infectious Diseases and Medical Microbiology. B76-B83. 1992
- POTENTIAL MANIPULATIONS TO RESTORE ABERRANT MYELOPOIESIS - THE ROLE OF NEW COLONY-STIMULATING FACTORS AND OTHER AGENTS. CANADIAN JOURNAL OF INFECTIOUS DISEASES, VOL 3, SUPPLEMENT B, AUGUST 1992. B76-B83. 1992
- RATIONALE FOR CLINICAL-APPLICATIONS OF COLONY-STIMULATING FACTORS (CSFS) AND OTHER MYELOPROTECTIVE AGENTS. COLONY-STIMULATING FACTORS IN CLINICAL PRACTICE. 3-16. 1992
- HISTORY OF THE PURIFICATION AND CHARACTERIZATION OF M-CSF AND GM-CSF - INTRODUCTION. CLINICAL RELEVANCE OF MACROPHAGE FUNCTION IN THE CANCER PATIENT. 1-4. 1991
- CARCINOEMBRYONIC ANTIGEN (CEA), ARGININE VASOPRESSIN (AV) AND CALCITONIN (CT) AS MARKERS OF EARLY SMALL-CELL LUNG-CANCER (SCLC) RELAPSE. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 224-224. 1987
- COMBINED MODALITY THERAPY WITH CHEMOTHERAPY (CT) AND RADIATION-THERAPY (RT) FOR PREVIOUSLY-UNTREATED STAGE-III SQUAMOUS AND LARGE CELL LUNG-CANCER. Clinical and Investigative Medicine. A124-A124. 1986
-
journal articles
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 41:2125-2133. 2023
- Christian Integrity Regained: Reformational Worldview Engagement for Everyday Medical Practice. Christian Bioethics. 26:163-176. 2020
- Review of Alireza Bagheri, ed.,Medical Futility: A Cross-National Study. American Journal of Bioethics. 14:52-53. 2014
- A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemotherapy and Pharmacology. 57:412-426. 2006
- Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemotherapy and Pharmacology. 57:427-435. 2006
- Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Supportive Care in Cancer. 14:11-21. 2006
- P-401 Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed + cisplatin versus cisplatin trial. Lung Cancer. 49:S220-S221. 2005
- P-422 Use of forced vital capacity (FVC) measurement for the clinical management of malignant pleural mesothelioma (MPM): Observations from the pemetrexed plus cisplatin versus cisplatin study. Lung Cancer. 49:S226-S226. 2005
- P-431 Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model. Lung Cancer. 49:S229-S229. 2005
- P-435 Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer. 49:S230-S231. 2005
- Malignant Pleural Mesothelioma. Chest. 126:1318-1329. 2004
- Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma. Cancer. 101:587-595. 2004
- Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer. 43:223-240. 2004
- 905 Documenting symptom palliation with chemotherapy using the LCSS-Meso: Results from the randomized trial of pemetrexed plus cisplatin vs cisplatin alone in patients with malignant pleural mesothelloma. European Journal of Cancer, Supplement. 1:S272-S272. 2003
- P-514 Can baseline quality of life parameters predict survival and other efficacy outcomes in malignant pleural mesothelioma?: Results from a 448-patient phase III trial. Lung Cancer. 41:S220-S220. 2003
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 21:2636-2644. 2003
- Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 21:1556-1561. 2003
- Pemetrexed safety and dosing strategy. Seminars in Oncology. 29:24-29. 2002
- Pemetrexed safety and dosing strategy. Seminars in Oncology. 29:24-29. 2002
- Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 20:431-437. 2002
- Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 20:3533-3544. 2002
- Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.. Molecular Cancer Therapeutics. 1:545-552. 2002
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer. 92:595-600. 2001
- Health-related quality of life of patients with malignant pleural mesothelioma treated with pemetrexed disodium. European Journal of Cancer. 37:s282. 2001
- The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer. Current Oncology. 8:50-59. 2001
- ALIMTA (TM) (pemetrexed, LY231514, MTA) in non-small cell lung cancer. Lung Cancer. 29:32. 2000
- Pemetrexed (ALIMTA), a novel multitargeted antifolate agent, is active alone and in combination in thoracic tumors. Lung Cancer. 29:38-39. 2000
- Phase II trial of MTA (AlimtaTM) and cisplatin in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Lung Cancer. 29:13-13. 2000
- Altered fractionation of radical radiaton therapy in the management of unresectable non-small-cell lung cancer. Current Oncology. 7:98-109. 2000
- The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer. Current Oncology. 7:162-172. 2000
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study. Journal of Clinical Oncology. 17:1194-1194. 1999
- Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.. Cancer Prevention and Control. 2:179-190. 1998
- The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Supportive Care in Cancer. 6:389-395. 1998
- The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. European Journal of Cancer. 34:31-36. 1998
- Assessing the Value of a New Pharmaceutical. Medical Care. 36:370-384. 1998
- Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. Journal of Clinical Oncology. 16:1174-1178. 1998
- Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16:1174-1178. 1998
- Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group.. Journal of Clinical Oncology. 15:3049-3059. 1997
- Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 33:S231-S231. 1997
- Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.. Cancer Prevention and Control. 1:241-248. 1997
- Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.. Cancer Prevention and Control. 1:249-259. 1997
- Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint. International Journal of Antimicrobial Agents. 8:263-275. 1997
- Are quality of life, patient preferences, and costs realistic outcomes for clinical trials?. Supportive Care in Cancer. 5:112-117. 1997
- Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.. Cancer Prevention and Control. 1:18-27. 1997
- Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. Journal of Clinical Oncology. 14:2083-2090. 1996
- Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 14:2083-2090. 1996
- Clinical Needs for Hematopoietic Growth Factors: Old and New. Cancer Investigation. 14:622-634. 1996
- 1204 Preventing nausea and vomiting during days 2–7 following high dose cisplatin chemotherapy (HDCP). European Journal of Cancer. 31:S251-S251. 1995
- Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Supportive Care in Cancer. 3:307-312. 1995
- Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Supportive Care in Cancer. 2:161-166. 1994
- Biological response modifiers and infectious diseases: Actual and potential therapeutic agents. International Journal of Antimicrobial Agents. 3:223-243. 1994
- The Risk of Varicella-Zoster Infections in Different Patient Populations: A Critical Review. Transfusion Medicine Reviews. 8:96-116. 1994
- Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 149:296-302. 1993
- Phase I Clinical Trial of Recombinant Human Interleukin-3 Combined With Carboplatin in the Treatment of Patients With Recurrent Ovarian Carcinoma. Journal of the National Cancer Institute. 85:823-825. 1993
- Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy. European Journal of Cancer. 29:S208-S208. 1993
- TRANSFORMING GROWTH FACTOR-BETA IS PRESENT IN ACTIVE FORM IN ASCITIC FLUID FROM HUMAN OVARIAN CARCINOMA. Journal of immunotherapy (Hagerstown, Md. : 1997). 13:61-61. 1993
- A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. International Journal of Gynecology and Obstetrics. 39:359-360. 1992
- The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. Journal of Pain and Symptom Management. 7:384-392. 1992
- ONDANSETRON VERSUS METOCLOPRAMIDE IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - A METAANALYSIS. International Journal of Oncology. 1:443-450. 1992
- Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cellular Immunology. 142:207-216. 1992
- A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecologic Oncology. 44:223-226. 1992
- Phase I Trial of Granulocyte-Macrophage Colony-Stimulating Factor With High-Dose Cisplatin and Etoposide for Treatment of Small-Cell Lung Cancer: A Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of the National Cancer Institute. 84:59-60. 1992
- Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 13:125-130. 1992
- Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor. Journal of the National Cancer Institute. 83:1748-1753. 1991
- A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Annals of Oncology. 2:681-686. 1991
- Simultaneous randomization to multiple dose levels and an active comparator as a means of determining the minimal effective dose of an investigational agent. Contemporary Clinical Trials. 12:696-696. 1991
- Superiority of Granisetron to Dexamethasone Plus Prochlorperazine in the Prevention of Chemotherapy-Induced Emesis. Journal of the National Cancer Institute. 83:1169-1173. 1991
- Biological response modifiers in the treatment of cancer and infectious diseases.. Cancer cells (Cold Spring Harbor, N.Y. : 1989). 3:243-244. 1991
- A phase I study of GM-CSF, cyclophosphamide (CP), and escalating doses of carboplatin (CBDCA) in chemotherapy-Naïve patients with ovarian cancer. Gynecologic Oncology. 40:169-170. 1991
- The Potential Role of Recombinant Hematopoietic Colony‐Stimulating Factors in Preventing Infections in the Immunocompromised Host. Canadian Journal of Infectious Diseases and Medical Microbiology. 2:74-88. 1991
- Small-cell carcinoma of the vagina. A clinicopathologic study.. Archives of Pathology and Laboratory Medicine. 114:728-731. 1990
- Gated magnetic resonance imaging of metastatic intracardiac malignant fibrous histiocytoma.. Canadian Association of Radiologists Journal. 41:96-97. 1990
- 5-Fluorouracil with Folinic Acid is Not Effective Against Metastatic Adenocarcinoma of the Lung. Cancer Investigation. 8:345-349. 1990
- Carcinoembryonic Antigen, Arginine Vasopressin and Calcitonin as Markers of Early Small-Cell Lung Cancer Relapse. Tumor Biology. 10:258-267. 1989
- Hodgkin's disease complicating non-Hodgkin's lymphoma.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 139:1157-1159. 1988
- Risk factors for varicella zoster disseminated infection among adult cancer patients with localized zoster. Cancer. 62:1641-1646. 1988
- Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy.. Clinical and Investigative Medicine. 11:377-379. 1988
- Varicella-Zoster Infection in Adult Cancer Patients. JAMA Internal Medicine. 148:1561-1561. 1988
- Varicella-zoster infection in adult cancer patients. A population study. JAMA Internal Medicine. 148:1561-1566. 1988
- THE CHALLENGE OF CURING CANCER - INCREASINGLY COMPLEX PATIENT-MANAGEMENT PLANNING. Humane medicine. 4:12-15. 1988
- Re-evaluating the cost of outpatient cancer chemotherapy.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 137:903-906. 1987
- Current approaches to the treatment of advanced-stage non-Hodgkin's lymphoma.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 136:29-36. 1987
- Canadian Cancer Care: Organizational Models. ACP journal club. 105:932-932. 1986
- Volume regulation of natural killer cells under hypotonic stress: Comparison with T and B cell subpopulations. Immunology Letters. 13:203-207. 1986
- Combined chemotherapy and radiation therapy for non-small-cell lung cancer.. Seminars in Oncology. 13:121-124. 1986
- Current approaches to the treatment of advanced-stage Hodgkin's disease.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 135:465-473. 1986
- Characterization of culture-induced cytotoxicity from human peripheral lymphocyte subpopulations. Cellular Immunology. 97:307-315. 1986
- Clinical significance of natural killer cell cytotoxicity: Need for proper data analysis in the design of clinical studies. European Journal of Cancer. 21:1287-1293. 1985
- Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.. Journal of Clinical Oncology. 3:1478-1485. 1985
- Treatment of pathologic stages IA and IIA Hodgkin's disease.. Journal of Clinical Oncology. 3:1563-1564. 1985
- Management of localized non-Hodgkin's lymphoma.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 133:559-564. 1985
- Early-stage Hodgkin's disease: current approaches to treatment.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 133:193-198. 1985
- The natural-killer-cell-associated HNK-1 (Leu-7) antibody reacts with hypertrophic and malignant prostatic epithelium. Cancer. 56:289-293. 1985
- Adenocarcinoma of the rectum metastatic to the oral cavity. Two cases and a review of the literature. Cancer. 54:1110-1112. 1984
- Systemic infection by Rhodotorula spp. in the immunocompromised host. Journal of Infection. 8:241-246. 1984
- DIFFERENTIATION OF THY 1-BEARING CELLS FROM PROGENITORS IN LONG-TERM BONE-MARROW CULTURES. Journal of Immunology. 124:597-601. 1980
- HYDROXYUREA KILLS B-CELL PRECURSORS AND MARKEDLY REDUCES FUNCTIONAL B-CELL ACTIVITY IN MOUSE BONE-MARROW. Journal of Immunology. 124:781-786. 1980
- THE USE OF HYDROXYUREA TO STUDY THE PROLIFERATIVE STATE OF T-CELL PRECURSORS (CFUT) IN MURINE BONE-MARROW. Experimental Hematology. 8:578-583. 1980
- Clinical isolation and characterization of aminoglycoside-resistant small colony variants of enterobacter aerogenes. American Journal of Medicine. 67:702-706. 1979
- Acute Lower Respiratory Disease. Primary Care - Clinics in Office Practice. 6:13-41. 1979
- Hemophilus influenzae f Cellulitis With Bacteremia, Peritonitis, and Pleuritis in an Adult With Nephrotic Syndrome. Southern Medical Journal. 71:1433-1434. 1978